AVTX-009 is a long-acting, next-generation humanized monoclonal antibody designed to target and bind to interleukin-1 beta (IL-1β). Developed by Avalo Therapeutics, it is engineered to suppress inflammatory pathways, extend dosing intervals, and build upon the clinical proof-of-concept established by the company's lead pipeline assets in treating prevalent immune-mediated inflammatory diseases and dermatological conditions.